Roth Capital Issues Positive Estimate for ZVRA Earnings

Key Points

• Roth Capital has raised its Q3 2025 earnings per share forecast for Zevra Therapeutics from ($0.04) to ($0.03), while the consensus estimate for the full year remains at ($1.95) per share.
• Zevra Therapeutics reported Q2 earnings of ($0.06) per share, missing expectations significantly, although revenue exceeded estimates at $25.88 million.
• Several analysts have issued updated ratings and price targets for Zevra Therapeutics, with a consensus price target of $23.71, reflecting a generally positive outlook on its stock.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Research analysts at Roth Capital lifted their Q3 2025 earnings estimates for Zevra Therapeutics in a research report issued on Wednesday, August 13th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.03) per share for the quarter, up from their prior forecast of ($0.04). The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics' Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at $0.86 EPS, FY2027 earnings at $1.63 EPS, FY2028 earnings at $2.05 EPS and FY2029 earnings at $2.48 EPS.

ZVRA has been the subject of several other research reports. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Cantor Fitzgerald increased their target price on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. JMP Securities lowered their target price on shares of Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen lowered shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 20th. Finally, HC Wainwright initiated coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a "buy" rating and a $26.00 target price on the stock. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Zevra Therapeutics has an average rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA traded down $0.23 during mid-day trading on Friday, hitting $9.20. The company's stock had a trading volume of 1,225,719 shares, compared to its average volume of 1,477,849. The stock has a market cap of $516.40 million, a price-to-earnings ratio of -43.81 and a beta of 1.87. The business's fifty day moving average is $10.56 and its two-hundred day moving average is $8.77. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 7.81. Zevra Therapeutics has a 1 year low of $6.19 and a 1 year high of $13.16.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Woodline Partners LP grew its stake in shares of Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock valued at $34,571,000 after buying an additional 476,032 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company's stock valued at $36,720,000 after buying an additional 550,000 shares during the period. Rubric Capital Management LP grew its stake in shares of Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company's stock valued at $17,253,000 after buying an additional 740,584 shares during the period. Altium Capital Management LLC grew its stake in shares of Zevra Therapeutics by 8.8% in the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company's stock valued at $15,429,000 after buying an additional 150,000 shares during the period. Finally, AIGH Capital Management LLC grew its stake in shares of Zevra Therapeutics by 82.4% in the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company's stock valued at $10,771,000 after buying an additional 649,495 shares during the period. Institutional investors and hedge funds own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.